Diabetes & Endocrinology Clinical Trials Update: Week 13, 2026
Published March 29, 2026 — 5 trials covered
By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.
Surgical or Medical Treatment
This Phase 4 trial is exploring whether bariatric surgery offers better long-term blood sugar control and fewer complications than intensive medical therapy for children and youth with type 2 diabetes who are candidates for surgery. For families facing difficult choices about managing young people’s diabetes amid obesity, this study may help clarify if surgery is a safer and more effective option compared to current medical treatments. It is recruiting in the United States at the Children's Hospital Medical Center, Cincinnati.
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
This Phase 3 trial is testing a new oral medication, orforglipron, designed to help adults with obesity or overweight manage their weight and blood sugar levels. Since it is a pill taken once daily, it could provide a more convenient option compared to existing treatments. The study is recruiting participants internationally, including in the United States, and may offer new opportunities for people living with obesity and type 2 diabetes.
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
This Phase 3 study focuses on adults who have obesity or overweight plus at least one related health condition, such as high blood pressure or diabetes. It is testing the same oral drug, orforglipron, to see if it can reduce body weight and improve overall health outcomes. The trial is ongoing in multiple countries and could offer a helpful new treatment option for managing weight and associated illnesses.
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
This Phase 3 global study is looking at baricitinib, an oral medication, to see if it can protect the insulin-producing cells in people newly diagnosed with type 1 diabetes. Keeping these cells working longer may help people manage their diabetes better and reduce complications over time. The study includes both children and adults and will follow participants for about 60 weeks.
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
This Phase 3 trial tested tirzepatide as a way to help adults with obesity or overweight keep weight off after they have already lost some. Maintaining weight loss can be challenging, and this medication might improve long-term health for those with related health problems. The study successfully completed enrollment with 441 participants in the United States.
This week’s trials highlight ongoing efforts to improve treatment options for both type 1 and type 2 diabetes, as well as obesity and related conditions. New medications being tested offer the potential for easier-to-use therapies that could improve blood sugar control and weight management. The surgical study for youth with type 2 diabetes may provide important insights into when surgery is the best choice. As research advances, patients and caregivers can look forward to more personalized and effective approaches to managing these chronic conditions.
TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.